The project is focused on understanding the underlying biology in kidney cells, with the goal of developing drug to treat kidney diseases, in particular Autosomal Dominant Polycystic Kidney Disease
(ADPKD). Following the elective removal of a polycystic kidney, otherwise normally discarded kidneys will be sent to Vertex Pharmaceuticals, Inc. to be analyzed.
